Zydus Cadila has received the Food and Drug Administration’s green light for Nelarabine injection.
The product is used to treat certain types of cancer.
The medication is a generic of Arranon injection.
Zydus has been granted a competitive generic therapy designation for the product.
[Read more: Zydus Cadila gets FDA blessing for generic Otezla]
Therefore, it is eligible for 180 days of exclusivity.